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Abstract
Objectives: Cartonectin is a novel adipokine of the C1q complement/TNF-related protein (CTRP) superfamily, with glucose
lowering effects, anti-inflammatory and cardio-protective properties. We sought to investigate circulating cartonectin
concentrations in subjects with type 2 diabetes mellitus (T2DM) as well as age and BMI matched control subjects. We also
examined the effects of a 2 hour 75 g oral glucose tolerance test (OGTT) on serum cartonectin concentrations in T2DM
subjects.
Design: Cross-sectional study [newly diagnosed (first discovery, not on any treatments) T2DM (n= 47) and control (n = 63)
subjects]. Serum cartonectin was measured by ELISA.
Results: Serum cartonectin concentrations were significantly lower in patients with T2DM compared to controls (P,0.05).
Furthermore, serum cartonectin was significantly negatively correlated with glucose and CRP, and significantly positively
correlated with leptin, in all subjects (n= 110). When subjected to multiple regression analysis, none of these variables were
predictive of serum cartonectin (P.0.05). There were no significant correlations in T2DM subjects (n= 47). In control
subjects (n= 63), serum cartonectin was significantly negatively correlated with CRP, and significantly positively correlated
with insulin, HOMA-IR and leptin. However, when subjected to multiple regression analysis, none of these variables were
predictive of serum cartonectin (P.0.05). Finally, serum cartonectin concentrations were significantly lower in T2DM
subjects after a 2 hour 75 g OGTT (P,0.01).
Conclusions: Cartonectin may serve as a novel biomarker for the prediction and early diagnosis of T2DM patients.
Furthermore, cartonectin and/or pharmacological agents that increase circulating cartonectin levels can represent a new
therapeutic field in the treatment of T2DM patients. Further research is needed to clarify these points.
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Introduction
Obesity has now achieved pandemic proportions and left
unchecked, leads to atherosclerosis by causing a repertoire of
metabolic and cardiovascular perturbations such as type 2 diabetes
mellitus (T2DM), dyslipidemia and hypertension [1]. Adipose
tissue produces several hormones and cytokines termed ‘adipo-
kines’ that have widespread effects on carbohydrate and lipid
metabolism, which appear to play an important role in the
pathogenesis of insulin resistance, diabetes, and atherosclerosis
[2,3]. Perturbations in adipokine concentrations have been
reported in insulin resistant states such as gestational diabetes
mellitus [4] and women with the Polycystic Ovary Syndrome
(PCOS) [5].
Presently, there has been intense interest in the adipokines of the
C1q complement/TNF-related protein (CTRP) superfamily.
Foremost in this group is the adipokine adiponectin that circulates
at high concentrations, and has insulin sensitizing, anti-inflamma-
tory and anti-atherogenic properties [6]. Altered circulating
adiponectin and adiponectin receptors levels have been described
in patients with T2DM and insulin resistant states such as women
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with PCOS [7,8]. Recently, CTRP3 (also known as cartonectin,
cartducin, CORS-26) was reported as a novel adipokine,
concentrations of which were lower in diet induced obese mice,
with glucose lowering effects achieved by suppressing hepatic
gluconeogenesis [9]. Cartonectin also decreases hepatic steatosis
[10]. Cartonectin, similar to adiponectin, has anti-inflammatory
properties [11–14]; cartonectin stimulates adipocyte adiponectin
secretion [15]. Akiyama et al. had shown that cartonectin
promotes proliferation and migration of endothelial cells and
suggested that cartonectin may be a novel angiogenic factor in the
formation of neo-intima following angioplasty [16]. Furthermore,
Maeda et al. had demonstrated a biological role of cartonectin in
promoting vascular smooth muscle cell proliferation in blood
vessel walls after injury [17]. Moreover, Yi et al. had shown that
cartonectin is a cardio-protective adipokine [18]; this could be via
its protective effects on bone marrow derived mesenchymal stem
cells, crucial for tissue regeneration in the ischemic myocardium
[19]. More recently, Zhou et al. had reported that cartonectin
promotes phosphate-induced smooth muscle vascular calcification
[20].
Therefore, we measured circulating cartonectin concentrations
in subjects with T2DM as well as age and BMI matched control
subjects. We also examined the effects of a 2 hour 75 g oral
glucose tolerance test (OGTT) on serum cartonectin concentra-
tions.
Materials and Methods
Ethics
The study was approved by the medical ethics committee of the
Affiliated Hospital of Jining Medical University, Shandong, China
and written informed consent was obtained from all participants,
in accordance with the guidelines in The Declaration of Helsinki
2000.
Subjects
Forty-seven newly diagnosed T2DM (as per the 1999 World
Health Organization criteria) [21] and sixty-three non-diabetic
subjects participated in this study (Table 1). Newly diagnosed
meant first discovery, and all T2DM subjects were not on any
treatments at the time when their blood samples were obtained for
this study. Exclusion criteria included a history of congestive heart
failure, liver or kidney disease, malignancy, signs of inflammation,
pregnancy and any drugs influencing body weight like corticoste-
roids or contraceptives. Subjects were patients of the Affiliated
Hospital of Jining Medical University.
After an overnight fast, blood samples were collected and
immediately centrifuged. A 2 hour 75 g OGTT was also
performed in subjects with T2DM. Serum was immediately
aliquoted on ice and stored at 280uC. All patients underwent
anthropometric measurements. Blood pressure was measured in a
sitting position within a quiet and calm environment after a rest of
at least 5 minutes. The average of three measurements was
obtained.
The primary aim of our study was to investigate serum
cartonectin concentrations in newly diagnosed (first discovery)
subjects with T2DM.
Biochemical and hormonal analysis
Assays for glucose, HbA1c (only in T2DM patients), total
cholesterol (TCH), HDL-cholesterol, LDL-cholesterol, VLDL-
cholesterol and triglycerides (TG) [Hitachi 7600 biochemical
automatic analyzer] as well as for insulin (Roche electrochemilu-
minescence analyzer) were performed. The estimate of insulin
resistance by HOMA-IR score was calculated as Io6Go/22.5,
where Io is the fasting insulin and Go is the fasting glucose, as
described by Matthews et al. [22]. The TCH/HDL and TG/
HDL ratios were calculated as indices of ischaemic heart disease
mortality and morbidity [23,24]. CRP concentrations in sera were
measured using a commercially available ELISA kit (Aviscera,
Santa Clara, USA) according to manufacturer’s protocol, with an
intra-assay coefficient of variation of less than 6%. Leptin
concentrations in sera were measured using a commercially
available ELISA kit (Aviscera, Santa Clara, USA) according to
manufacturer’s protocol, with an intra-assay coefficient of
variation of less than 8%. Adiponectin concentrations in sera
were measured using a commercially available ELISA kit
(Biovision, Milpitas, USA) according to manufacturer’s protocol,
with an intra-assay coefficient of variation of less than 8%.
Cartonectin concentrations in sera were measured using a
commercially available ELISA kit (USCN Life Science, Inc.,
Wuhan, China) according to manufacturer’s protocol, with an
intra-assay coefficient of variation of less than 10%.
Statistical analysis
Data were analysed by Mann-Whitney U test and Wilcoxon
matched pairs test. Data are medians (interquartile range).
Spearman Rank correlation was used for calculation of associa-
tions between variables. Subsequently, if individual bivariate
correlations achieved statistical significance, variables were entered
into a linear regression model and multiple regression analysis was
performed. All statistical analyses were performed using SPSS
version 22.0 (SPSS, Inc.). P,0.05 was considered significant.
Results
Table 1 shows the anthropometric, biochemical and hormonal
parameters in all subjects. Systolic Blood Pressure (SBP), Diastolic
Blood Pressure (DBP), TCH, TG, TCH/HDL ratio, TG/HDL
ratio, glucose, HOMA-IR and CRP were significantly higher,
whereas leptin and adiponectin were significantly lower in T2DM
subjects.
Serum cartonectin concentrations were significantly lower in
patients with T2DM compared to controls [150.2 (72.9–288.7) vs.
248.9 (115.0–321.2) ng/ml; P,0.05: Table 1].
Furthermore, women had higher serum adiponectin concen-
trations [10.6 (7.0–24.8) vs. 7.2 (5.4–12.4)mg/ml; P,0.05]
compared to men; however, there were no significant difference
with respect to serum cartonectin concentrations [224.1 (98.8–
321.2) vs. 188.9 (100.7–304.0) ng/ml; P.0.05].
Effects of a 2 hour 75 g OGTT in T2DM subjects on serum
cartonectin concentrations
Glucose and insulin concentrations were significantly higher in
T2DM subjects after a 2 hour 75 g OGTT (Figure1A: **P,0.01
and Figure1B: **P,0.01, respectively).
Conversely, serum cartonectin concentrations were significantly
lower in T2DM subjects after a 2 hour 75 g OGTT (Figure1C:
**P,0.01).
Correlation of cartonectin with covariates
Spearman Rank analysis showed that serum cartonectin was
significantly negatively correlated with glucose and CRP, and
significantly positively correlated with leptin, in all subjects
(n=110) [Table 2]. When subjected to multiple regression
analysis, none of these variables were predictive of serum
cartonectin (P.0.05). There were no significant correlations in
T2DM subjects (n=47) [Table 2]. In control subjects (n=63),
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serum cartonectin was significantly negatively correlated with
CRP, and significantly positively correlated with insulin, HOMA-
IR and leptin [Table 2]. However, when subjected to multiple
regression analysis, none of these variables were predictive of
serum cartonectin (P.0.05).
Discussion
We report for the first time that serum cartonectin concentra-
tions are significantly lower in newly diagnosed (first discovery)
patients with T2DM compared to control subjects. We also found
that serum adiponectin concentrations were significantly lower in
T2DM compared to control subjects, in keeping with the current
research literature [25]. Both cartonectin and adiponectin have
apparently similar functions i.e. insulin sensitizing, anti-inflamma-
tory and cardio-protective properties [26], and may function
synergistically. Notably, Wolfing et al. had shown that cartonectin
stimulates adipocyte adiponectin secretion [15]. Furthermore, we
had observed significantly lower leptin concentrations in our newly
diagnosed (first discovery) T2DM subjects (median HbA1c: 7.3%).
This is similar with previous publications describing lower leptin
concentrations in subjects with poorly controlled T2DM [27,28].
The lower serum cartonectin concentrations in patients with
T2DM is bewildering given that Choi et al. had recently reported
that plasma cartonectin was significantly higher in patients with
T2DM [29], and that a three month combined exercise program
significantly decreased cartonectin levels in obese Korean women
[30]. Interestingly, the same researchers also reported that serum
cartonectin was not significantly lower in subjects with the
metabolic syndrome compared to controls [31]. More recently,
Choi et al. had published data reporting significantly lower
circulating cartonectin concentrations in patients with acute
coronary syndrome or stable angina pectoris, compared to control
subjects [32]. A possible explanation of elevated cartonectin levels
in T2DM observed by Choi et al. [29] could be the effect of
medications taken by their study subjects as discussed in their
following manuscript [31]. We have reported that metformin
significantly increases circulating cartonectin concentrations in
insulin resistant women with PCOS [33]. The findings from the
current study support this notion.
Also, we present novel data that serum cartonectin concentra-
tions were significantly lower in T2DM patients after a 2 hour
75 g OGTT. In contrast, glucose and insulin concentrations were
significantly higher after the 2 hour 75 g OGTT. Therefore,
glucose and/or insulin could account for the reduction in serum
cartonectin concentrations. Since a recent in vitro study demon-
strated that cartonectin concentrations were increased by insulin
[34], and that glucose was significantly altered (lower) but not
insulin in our T2DM patients, we propose that changes in glucose
metabolism are more likely to explain our findings.
A limitation of this study is that it comprised of only Chinese
subjects and thus our observations may not apply to other
populations. Further studies are needed to elucidate this point.
Notwithstanding, our results contribute to the paucity of human
studies on cartonectin and raises interesting questions on the
factors that regulate cartonectin concentrations in human subjects
with metabolic and cardiovascular complications.
Our data supports cartonectin as a potential novel biomarker
for the prediction and early diagnosis of T2DM patients.
Furthermore, cartonectin and/or pharmacological agents that
increase circulating cartonectin levels can represent a new
Table 1. Clinical, hormonal and metabolic features of study subjects.
Variable T2DM (n=47) Controls (n=63) Significance
Sex (female/male) 22/25 28/35
Age (year) 55.0 (41.0–60.0) 47.0 (40.0–54.0) NS
BMI (kg/m2) 26.0 (22.9–28.4) 24.2 (22.0–26.4) NS
SBP (mm Hg) 140.0 (125.0–150.0) 120.0 (108.0–127.0) P,0.01
DBP (mm Hg) 85.0 (75.0–95.0) 75.0 (68.0–83.0) P,0.01
TCH (mmol/L) 5.2 (4.4–5.9) 4.6 (4.1–5.1) P,0.01
HDL-cholesterol (mmol/L) 1.4 (1.1–1.6) 1.4 (1.2–1.5) NS
LDL-cholesterol (mmol/L) 3.0 (2.4–3.3) 2.7 (2.3–3.1) NS
VLDL-cholesterol (mmol/L) 0.7 (0.4–1.2) 0.6 (0.4–0.7) NS
Triglycerides (mmol/L) 1.6 (0.9–2.5) 1.0 (0.8–1.4) P,0.01
TCH/HDL 3.8 (3.0–4.2) 3.5 (3.1–3.8) P,0.05
TG/HDL 0.3 (0.2–0.5) 0.2 (0.2–0.3) P,0.05
Glucose (mmol/L) 7.3 (6.7–9.3) 4.9 (4.6–5.3) P,0.01
Insulin (pmol/L) 69.9 (32.6–92.6) 54.3 (36.7–72.0) NS
HOMA-IR 3.1 (1.8–4.4) 1.7 (1.1–2.3) P,0.01
HbA1C (%) 7.3 (6.3–8.8)
CRP (mg/l) 4.3 (2.2–8.7) 1.8 (0.8–2.6) P,0.01
Leptin (ng/ml) 2.0 (1.0–5.4) 8.0 (3.1–12.0) P,0.01
Adiponectin (mg/ml) 8.3 (6.1–21.4) 11.0 (8.4–16.2) P,0.05
Cartonectin (ng/ml) 150.2 (72.9–288.7) 248.9 (115.0–321.2) P,0.05
Data are median (interquartile range). Group comparison by Mann-Whitney U test.
BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; TCH = total cholesterol; TG = triglycerides; DBP = diastolic blood pressure;
NS = not significant.
doi:10.1371/journal.pone.0112931.t001
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Figure 1. Effects of a 2 hour 75 g OGTT on serum glucose (A), insulin (B) and cartonectin (C) concentrations in T2DM subjects
(n=47). Group comparison by Wilcoxon matched pairs test. **P,0?01.
doi:10.1371/journal.pone.0112931.g001
Table 2. Linear regression analysis of variables associated with Cartonectin.
Subjects All (n=110) T2DM (n=47) Control (n=63)
Variable r P r P r P
Age (year) 0.008 0.930 0.204 0.168 20.134 0.297
BMI (kg/m2) 20.053 0.580 0.020 0.893 20.013 0.918
SBP (mm Hg) 0.073 0.446 0.116 0.438 0.201 0.115
DBP (mm Hg) 0.049 0.612 0.079 0.597 0.207 0.103
TCH (mmol/L) 20.158 0.099 20.004 0.977 20.169 0.185
HDL-cholesterol (mmol/L) 20.031 0.747 20.114 0.446 0.064 0.619
LDL-cholesterol (mmol/L) 20.122 0.204 20.047 0.753 20.064 0.617
VLDL-cholesterol (mmol/L) 20.027 0.778 0.223 0.132 20.243 0.055
Triglycerides (mmol/L) 20.014 0.888 0.012 0.936 0.145 0.255
TCH/HDL 20.099 0.305 0.075 0.618 20.136 0.289
TG/HDL 0.045 0.642 0.005 0.974 0.229 0.070
Glucose (mmol/L) 20.201* 0.035 0.116 0.436 20.194 0.127
Insulin (pmol/L) 0.159 0.096 0.092 0.537 0.388** 0.002
HOMA-IR 0.083 0.389 0.100 0.503 0.341** 0.006
HbA1C (%) 20.179 0.229
CRP (mg/l) 20.223* 0.019 0.064 0.667 20.361** 0.004
Leptin (ng/ml) 0.274** 0.004 0.196 0.187 0.263* 0.037
Adiponectin (mg/ml) 20.052 0.589 20.080 0.594 20.135 0.292
Spearman Rank correlation was used for calculation of associations between variables. If individual bivariate correlations achieved statistical significance, multiple
regression analysis with Cartonectin as dependent variable was performed to test the joint effect of these parameters on Cartonectin. Multiple regression analysis
contained glucose, CRP and leptin (all subjects); insulin, HOMA-IR, CRP and leptin (control subjects). *P,0.05; **P,0.01.
doi:10.1371/journal.pone.0112931.t002
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therapeutic field in the treatment of T2DM patients. Further
research is needed to clarify these points.
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